Safety and Quality-Of-Life (QOL) Assessments in the Open-Label, Multicenter, Phase 3b, Expanded Access Study of Everolimus in Patients with Advanced Neuroendocrine Tumors (NET)

Marianne Pavel1; Nicole Unger2; Ivan Borbath3; Sergio Ricci4; Tsann-Long Hwang5; Young Suk Park6; Jiří Tomášek7; Hussein Raef8; Sudsawat Laohavinij9; Santosh Sutradhar10; Lisa Jean-Louis11; Ashok Panneerselvam11; Stephen Saletan11; Sotirios G. Stergiopoulos11; and Oliver Bechter12

1Charité Universitätsmedizin Berlin/Campus Virchow Klinikum, Berlin, Germany
2University of Duisburg-Essen, Essen, Germany
3Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
4Presidio Ospedaliero Santa Chiara, Pisa, Italy
5Chang Gung Memorial Hospital/Chang Gung University, Lin-Kou, Taiwan
6Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
7Masaryk Memorial Cancer Institute, Brno, Czech Republic
8King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
9Rajavithi Hospital, Bangkok, Thailand
10Novartis Pharma S.A.S; Rueil-Malmaison, France
11Novartis Pharmaceuticals Corporation, Florham Park, NJ, USA
12University Hospital Leuven, Leuven Cancer Institute, Leuven, Belgium

Background: RADIANT-2 and RADIANT-3 phase 3 trials demonstrated efficacy of everolimus in patients with advanced NET. In RADIANT-3, everolimus significantly prolonged progression-free survival (PFS) versus placebo (P<0.001) in patients with pancreatic NET (pNET). Preceding everolimus approval in the US and Europe for advanced pNET, an expanded-access protocol was launched to provide access to everolimus and gather additional data on everolimus safety and QOL impact on patients with advanced NET.

Methods: Patients ≥18 years with biopsy-proven NET and WHO performance status 0-2 were enrolled from April 21, 2011–April 20, 2012. Main exclusion criteria were poorly differentiated NET and cytotoxic therapy within 4 weeks of enrollment. Everolimus (10 mg/d) was administered until disease progression, unacceptable toxicity, discontinuation, death, commercial availability of everolimus, or May 30, 2012, whichever came first. Objectives included safety of everolimus and change in health-related QOL. QOL was assessed at baseline; cycles 1, 2, and 3; and every 3 cycles until end of treatment (EOT) using EORTC QLQ-C30 and the NET-specific EORTC QLQ-GINET21.

Results: Full analysis set (N=246; pNET, n=126)/safety analysis set (N=240; pNET, n=123). Adverse events (AEs) occurring in ≥10% of pNET/non-pNET patients included hyperglycemia (12.2%/5.1%), diarrhea (10.6%/31.6%), stomatitis (9.8%/11.1%), nausea (8.1%/10.3%), anemia (5.7%/11.1%), abdominal pain (4.1%/10.3%), and fatigue (0.8%/14.5%). Grade 3/4 AE frequency was 42.3% (pNET) and 69.2% (non-pNET). In pNET patients, global health status remained stable through EOT (−3.9 point QLQ-C30 change from baseline, n=86), with a −13.0-point change in non-pNET patients (n=69). Baseline and EOT functional cognitive, emotional,
physical, role, and social functioning scale scores were similar. QLQ-GINET21 symptom and functional assessment changes to EOT were <9 points for all scores.

**Conclusion:** Everolimus was well tolerated in patients with advanced NET. AEs were similar to those previously reported. Everolimus maintained QOL through EOT in pNET patients, as assessed by patients and QLQ-C30/QLQ-GINET21.

*Supported by Novartis Pharmaceuticals Corporation.*